stent

SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection

Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Daniel Zanuttini (Arg.) presents “Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection”. This is the 8th clinical case presented by SOLACI Peripheral. The purpose of this space is to encourage and further the exchange of experiences<a href="https://solaci.org/en/2021/08/24/solaci-peripheral-type-ib-endoleak-correction-in-patient-after-minimally-invasive-hybrid-treatment-in-type-a-aortic-disection/" title="Read more" >...</a>

Resonancia vs FFR en lesiones no culpables del infarto

New Markers of Aortic Stenosis Define Asymptomatic Patients

Asymptomatic aortic stenosis has been keeping us in tense stillness. However, there are new markers capable of identifying patients that might benefit from earlier intervention. In this regard, cardiovascular magnetic resonance (CMR) has been gaining its well-deserved place in cardiology and now more specifically in aortic stenosis.&nbsp; This study sought to validate CMR markers of<a href="https://solaci.org/en/2021/08/19/new-markers-of-aortic-stenosis-define-asymptomatic-patients/" title="Read more" >...</a>

IVUS vs OCT para guiar la angioplastia ¿Cuál elegir?

How Bad is Malapposition? OCT Findings and Events

Most post-angioplasty findings with optical coherence tomography (OCT) were not associated with clinical adverse events. Exceptions were small intra-stent area, and significant malapposition. Suboptimal findings after angioplasty are very common (almost expected), although their clinical implications are uncertain. This registry—recently published in JACC—was developed in an attempt to answer these questions. The analysis included a<a href="https://solaci.org/en/2021/08/13/how-bad-is-malapposition-oct-findings-and-events/" title="Read more" >...</a>

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

The Long Marathon of Ultrathin vs. 2nd Generation Thin-Strut DES

After 2.5 years of non-stop racing, ultrathin-strut drug-eluting stents (DES) reached the finish line before 2nd generation thin-strut DES. The advantage was in terms of clinically justified lesion revascularization, while rates of infarction, stent thrombosis, cardiac death, and all-cause death were similar. After failure at trying to create new generations of DES based on drugs<a href="https://solaci.org/en/2021/08/13/the-long-marathon-of-ultrathin-vs-2nd-generation-thin-strut-des/" title="Read more" >...</a>

SOLACI-CACI 2021 | International Sessions with the Most Renowned Societies Worldwide

&nbsp; INTERNATIONAL SESSIONS WITH THE MOST RENOWNED SOCIETIES WORLDWIDE Appealing sessions on the most relevant current topics in interventional cardiology will be at the forefront of a virtual, interactive event you do not want to miss! Save the date: August 2-6, 2021 Register now for FREE Learn more about the international joint sessions featured in<a href="https://solaci.org/en/2021/07/23/solaci-caci-2021-international-sessions-with-the-most-renowned-societies-worldwide/" title="Read more" >...</a>

Recomendaciones de la ACC con el nuevo coronavirus

Anosmia 1 Year After a COVID-19 Diagnosis

The number of people with post-COVID-19 syndrome seems to be growing exponentially, so we need long-term data to help physicians advise patients correctly. Among the many persistent symptoms, post-COVID-19 anosmia has good prognosis and almost full recovery at 1&nbsp;year. In April, 2020, these same authors published a cohort of almost 100 COVID-19 positive patients (positive<a href="https://solaci.org/en/2021/07/22/anosmia-1-year-after-a-covid-19-diagnosis/" title="Read more" >...</a>

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Efficacy of the Novavax Vaccine Against COVID-19: Nanoparticle Technology to the Test

In healthy adults, two doses of the NVX-CoV2373 (Novavax) vaccine has an efficacy of almost 90% against SARS-CoV-2 infection in all severity types. Furthermore, it has proven to be effective against the alpha variant (B.1.1.7). The Novavax vaccine is a recombinant nanoparticle containing full-length spike glycoprotein. It had already been shown to be safe and<a href="https://solaci.org/en/2021/07/16/efficacy-of-the-novavax-vaccine-against-covid-19-nanoparticle-technology-to-the-test/" title="Read more" >...</a>

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

Novel DES Technology Promises to Become the Next DES Generation

The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing. Accelerated endothelial healing after antiproliferative drug release may limit the long-term inflammatory response. This multicenter, single-blind study included 1600&nbsp;patients who were randomized 2:1 to receive drug-eluting stent Supreme vs. a classic permanent-polymer everolimus-eluting<a href="https://solaci.org/en/2021/07/13/novel-des-technology-promises-to-become-the-next-des-generation/" title="Read more" >...</a>

TAVI en insuficiencia aórtica pura

TAVR Durability Becomes Irrelevant after TRANSIT Outcomes

The international registry TRANSIT has shown treating degenerated transcatheter aortic valves (TAVs) with a second TAVR is safe and effective. These finding are of crucial importance to the definite adoption of TAVR in the lower risk, younger population.&nbsp; Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in severe aortic stenosis treatment.&nbsp; Technological innovation<a href="https://solaci.org/en/2021/07/06/tavr-durability-becomes-irrelevant-after-transit-outcomes/" title="Read more" >...</a>

SOLACI PERIPHERAL | 7th Clinical Case: Percutaneous Treatment for Nutcracker Syndrome

New SOLACI PERIPHERAL clinical case to keep learning among peers! Dr. Carlos Eduardo Díniz Couto shares a “Nutcracker” case from Belo Horizonte, Brazil. This is the 7th clinical case presented by SOLACI Peripheral on the SOLACI website. This space is intended to further promote and share experiences and opinions in order to continue improving our<a href="https://solaci.org/en/2021/07/06/solaci-peripheral-7th-clinical-case-percutaneous-treatment-for-nutcracker-syndrome/" title="Read more" >...</a>

Top